Skip to main
PFE

Pfizer (PFE) Stock Forecast & Price Target

Pfizer (PFE) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 33%
Buy 8%
Hold 42%
Sell 17%
Strong Sell 0%

Bulls say

Pfizer is a global biopharmaceutical company with a strong focus on developing and selling prescription drugs and vaccines, with international sales being a major contributor to their revenue. Their recent acquisition of Metsera adds potential for growth in the obesity market and their strong infrastructure and commercial expertise should allow them to advance the Metsera portfolio rapidly and reach its full potential. Furthermore, positive bioavailability and food-effect data from their oral programs could be impactful catalysts that validate the platform's differentiation and expand the addressable market opportunity.

Bears say

Pfizer is facing several headwinds in the near term with challenges to its key patents in the cardiovascular and vaccine market. Additionally, the company is facing risks in terms of new growth drivers, with potential negative trial results for its pipeline drugs. Furthermore, Pfizer's reputation and potential access to emerging markets could be negatively affected by ongoing controversies surrounding COVID-19 vaccines.

Pfizer (PFE) has been analyzed by 12 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 8% recommend Buy, 42% suggest Holding, 17% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pfizer and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pfizer (PFE) Forecast

Analysts have given Pfizer (PFE) a Buy based on their latest research and market trends.

According to 12 analysts, Pfizer (PFE) has a Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pfizer (PFE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.